Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Rhea-AI Summary

Palvella Therapeutics (Nasdaq: PVLA) announced that Founder and CEO Wes Kaupinen will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 4:00 p.m. ET.

A live webcast will be available on the company's Events and Presentations page at www.palvellatx.com, and an archived replay will be accessible for approximately 90 days after the presentation.

WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 4:00 p.m. ET.

A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved or cleared by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com

Media
Marcy Nanus
Managing Partner, Trilon Advisors LLC
mnanus@trilonadvisors.com

FAQ

When will Palvella Therapeutics (PVLA) present at the Stifel 2025 Healthcare Conference?

Palvella will present on Wednesday, November 12, 2025 at 4:00 p.m. ET.

Who from Palvella (PVLA) is presenting at the Stifel 2025 Healthcare Conference?

Wes Kaupinen, Founder and Chief Executive Officer, will deliver the presentation.

How can investors watch Palvella's (PVLA) Stifel 2025 presentation live?

Watch the live webcast on the Events and Presentations page at www.palvellatx.com.

Will there be a replay of Palvella's (PVLA) Stifel 2025 presentation and for how long?

Yes, an archived replay will be available for approximately 90 days after the presentation.

Where on Palvella's (PVLA) site will the Stifel 2025 webcast be posted?

The webcast will be posted in the Events and Presentations section of www.palvellatx.com.

Is the Stifel 2025 presentation by Palvella (PVLA) expected to include clinical updates?

The announcement confirms the company will present; specific presentation content such as clinical updates was not specified.